EGFR mutations are a crucial therapeutic target in non-small-cell lung cancer (NSCLC) harbouring somatic mutations in the tyrosine kinase domain of EGFR. These EGFR mutations provoke activation of the STAT and Akt signalling pathways, and both promote cell survival.1 Additionally, downregulation of...
In this open-label, dose-escalation and dose-expansion phase 1 trial, the potential for improved anti-tumor activity by combining amivantamab, an EGFR-MET bispecific antibody, with lazertinib, a third-generation EGFR TKI, was evaluated in patients with EGFR-mutant NSCLC whose disease progressed...
In the CNS response analysis set, the ORR was 64% [17], suggesting encouraging results with osimertinib in EGFR-mutant NSCLC patients with brain metastases. The phase II AURA2 trial (NCT02094261) demonstrated similar results [18] (Table 2). The study enrolled 210 T790M-positive metastatic ...
small cell lung cancer (NSCLC) harboring classical EGFR mutations (4). Indeed, the EGFR mutated disease still represents the paradigm of precision medicine, in which a personalized approach is required irrespective of disease stage. In its “International Multidisciplinary Team (iMDT) corner”, the ...
However, the exact mechanism of how EGFR-mutant NSCLC contributes to BM remains unknown. Herein, we found the protein WNT5A, was significantly downregulated in BM tissues and EGFR-mutant samples. In addition, the overexpression of WNT5A inhibited the growth, migration, and invasion of EGFR-...
Aberrant activation of mesenchymal epithelial transition(MET) has been considered to mediate primary and acquired resistance to epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors(TKIs)in EGFR-mutant non-small-cell lung cancer(NSCLC). However, mechanisms underlying this process are not ...
Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear mechanisms. Hypothesizing that EGFR mutations alter tumor-immune interactions, we co
MUTATIONS INthe epidermal growth factor receptor (EGFR) gene were discovered in 2004. These mutations, localized most commonly to exon 19 or 21, vary in prevalence from 15% to 35% of all cases of lung adenocarcinoma. Similar to the case with various oncogene-addicted cancers,...
NSCLC: Non-small cell lung cancer EGFR: Epidermal growth factor receptor EGFR-TKIs: EGFR tyrosine kinase inhibitors TKI: Tyrosine kinase inhibitor AR: Acquired resistance SCLC: Small-cell lung cancer FGFR: Fibroblast growth factor receptor AJCC: American Joint Committee on Cancer ECOG: ...
Osimertinib is a third-generation tyrosine kinase inhibitor clinically approved for first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients. Although an impressive drug response is initially observed, in most of tumors, resistance occurs after different time and an alternative ...